Received 15 June 2005; revised 12 September 2005; accepted 7 October 2005 Effects of dissociated g lucocorticoids on OPG an d RANKL in osteoblastic cells E.L. Humphrey a, J.H.H. Williams a,b, M.W.J. Da vie a, M.J. Marshall a, 姓姓 : 姓姓姓 姓姓 : 姓姓姓姓姓姓姓姓姓 姓姓 :9 1390496
26
Embed
E.L. Humphrey a, J.H.H. Williams a,b, M.W.J. Davie a, M.J. Marshall a, 姓名 : 萬映汝
Received 15 June 2005; revised 12 September 2005; accepted 7 October 2005 Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. E.L. Humphrey a, J.H.H. Williams a,b, M.W.J. Davie a, M.J. Marshall a, 姓名 : 萬映汝 系級 : 生物科技學系四年級 - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Received 15 June 2005; revised 12 September 2005; accepted 7 October 2005
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cellsE.L. Humphrey a, J.H.H. Williams a,b, M.W.J. Davie a, M.J. Marshall a, 姓名 : 萬映汝
系級 : 生物科技學系四年級 學號 :91390496
AbbreviationAbbreviation GIOP- GIOP- glucocorticoid-induced osteoporosis GR- glucocorticoid receptor hFOB- human fetal osteoblast nGRE- negative glucocorticoid response ele
ment OPG- osteoprotegerin 促骨生成蛋白受體為蝕骨
細胞分化抑制因子 RANKL- receptor activator of nuclear factor
kappa B ligand 促骨生成蛋白結合子為促進蝕骨細胞生成的主因子
Introduction Glucocorticoid treatment often leads to u
nwanted side effects including weight gain, skin thinning, osteopenia, eye defects, depression, diabetes, adrenal insufficiency and peptic ulcers ,但長期使用 Glucocorticoid 治療會導致 GIOP.
Adult bone remodeling is carried out by osteoblasts and osteoclasts, which are controlled by various hormones, cytokines and growth factors.
RNA extraction and first strand cDNA synthesis Qiagen RNeasy kitReal-time PCR 利用利用 the ABI Assays on Demand primers and Taqman universal PCR master mix
在 MG63 cell 中 dexamethasone 抑制效果最佳
在 hFOB cell 中 dexamethasone 抑制效果最佳
The potency of each GR ligand is described by itsIC50, and its effectiveness is described by the maximuminhibition.
1010 倍倍66 倍倍
1212倍倍
達最大抑制達最大抑制 OPGOPG 產量產量一半所需的化合物濃一半所需的化合物濃
度度
在 MG63cell 中加入 10μM 的 anti-glucocorticoid RU486
OPGOPG 濃度皆提高濃度皆提高
control 為 anti-glucocorticoid control RU43044
( in MG63 cell )
control 為 anti-glucocorticoid control RU43044
(in hFOB cell )
control 為 inactive racemer AL438-F2( in MG63 cell )
control 為 inactive racemer AL438-F2( in hFOB cell )